Valuation: Lexeo Therapeutics, Inc.

Market Cap 368M 322M 297M 274M 516M 35.46B 527M 3.55B 1.4B 17.37B 1.38B 1.35B 59.79B P/E 2026 *
-4x
P/E 2027 * -3.51x
Enterprise Value 225M 197M 182M 167M 316M 21.69B 323M 2.17B 854M 10.62B 846M 827M 36.57B EV / Sales 2026 *
-
EV / Sales 2027 * 16.1x
Free-Float
99.39%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lexeo Therapeutics, Inc.

1 day+2.85%
1 week-2.70%
Current month+0.75%
1 month-4.87%
3 months-32.13%
6 months-36.54%
Current year-52.77%
1 week 4.4
Extreme 4.4
4.9
1 month 4.33
Extreme 4.33
5.38
Current year 4.03
Extreme 4.03
10.75
1 year 3.6
Extreme 3.6
10.99
3 years 1.45
Extreme 1.45
22.33
5 years 1.45
Extreme 1.45
22.33
10 years 1.45
Extreme 1.45
22.33
Manager TitleAgeSince
Chief Executive Officer 46 01/01/2020
Director of Finance/CFO 50 15/08/2025
Chief Tech/Sci/R&D Officer 62 20/01/2026
Director TitleAgeSince
Director/Board Member 46 01/01/2020
Chairman 72 01/01/2021
Director/Board Member 61 01/11/2020
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Sell

Chief Technology Officer

-22,306 0.0284%
7/1/26 A Sell

Chief Executive Officer

-25,947 0.0330%
7/1/26 A Sell

Chief Financial Officer

-4,641 0.0059%
Change 5-day change 1-year change 3-year change Capi.($)
+2.85%-2.70%+13.01% - 368M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.21%-2.63%+37.79%+184.05% 23.39B
Weighted average by Cap. -2.79%-2.36%+39.51%+143.13%

Financials

2026 *2027 *
Net sales - 6.11M 5.34M 4.93M 4.54M 8.56M 589M 8.75M 58.9M 23.17M 288M 22.95M 22.45M 992M
Net income -97.88M -85.54M -78.93M -72.75M -137M -9.43B -140M -943M -371M -4.62B -368M -360M -15.89B -123M -108M -99.29M -91.52M -173M -11.86B -176M -1.19B -467M -5.81B -462M -452M -19.99B
Net Debt -143M -125M -115M -106M -200M -13.77B -205M -1.38B -542M -6.74B -537M -525M -23.22B -270M -236M -217M -200M -378M -25.97B -386M -2.6B -1.02B -12.72B -1.01B -991M -43.79B
Logo Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Employees
59
Date Price Change Volume
17/07/26 $4.690 +2.85% 730,135
16/07/26 $4.560 -3.80% 780,226
15/07/26 $4.740 +2.60% 772,115
14/07/26 $4.620 -0.54% 606,557
13/07/26 $4.645 -3.63% 584,310
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.690USD
Average target price
20.89USD
Spread / Average Target
+345.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXEO Stock